BioSpace News Archive

Veteran Leader Brings Extensive Experience from Both Pharma and Device Industries

Study Aims to Assess Whether Closed-Loop Neuromodulation Could Help Manage Medically Refractory Obesity

Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community

Combined portfolio enables Agilent to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis

Focused primarily on biologics, a core R&D platform on which the company continues to build for future growth, the R&D campus further augments the company’s significant U.S. presence.

WellCare Health Plans, Inc. and AbleTo, a leading provider of virtual behavioral healthcare, announced the launch of a new program to serve WellCare’s Medicare Advantage members in New York.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company is continuing its commitment to the Scoliosis Research Society as a Double Diamond sponsor of the 26th International Meeting on Advanced Spine Techniques (IMAST) being held July 17-20, 2019

Integrated end-to-end patient and supply chain management platform to support cell and gene therapies

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, announced that its Audit Committee and Board of Directors appointed Moss Adams LLP as the Company’s new independent auditor.

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with atopic dermatitis (AD).